VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting
12. Oktober 2023 09:00 ET
|
VBL Therapeutics
Approved Merger with Notable Labs and All Other Proposals Merger Expected to Close and Begin Trading as Combined Company Under the NTBL Ticker on Nasdaq Next Week, Subject to Effectiveness of...
VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meeting
04. Oktober 2023 08:00 ET
|
VBL Therapeutics
MODI’IN, Israel and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), reminds its shareholders to vote in favor of the previously announced proposed merger (the...
VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC
06. September 2023 08:00 ET
|
VBL Therapeutics
Merger with Notable expected to close in mid-October, subject to shareholder approval Special shareholder meeting scheduled for October 12, 2023 MODI’IN, Israel and NEW YORK, Sept. 06, 2023 (GLOBE...
VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
14. August 2023 08:00 ET
|
VBL Therapeutics
Merger with Notable expected to close in late September or October, subject to VBL’s S-4 registration statement being declared effective and shareholder approval $24.3 million in cash and cash...
VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
15. Mai 2023 16:01 ET
|
VBL Therapeutics
MODI’IN, Israel and NEW YORK, May 15, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced financial results for the first quarter ended March 31, 2023, and provided a...
VBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
14. März 2023 08:00 ET
|
VBL Therapeutics
MODIIN, Israel and NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), today announced financial results for the fiscal year ended December 31, 2022, and provided a...
VBL Therapeutics Announces Closing of Sale of Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash
09. März 2023 08:00 ET
|
VBL Therapeutics
MODIIN, Israel and NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today that it has closed on the previously announced sale of its manufacturing facility in...
VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement
23. Februar 2023 07:00 ET
|
VBL Therapeutics
Merger will create Nasdaq-listed, clinical-stage therapeutic platform company developing new precision medicines for patient populations selected through Notable’s proprietary Predictive Precision...
VBL Therapeutics Announces Agreement to Sell Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash
16. Februar 2023 08:00 ET
|
VBL Therapeutics
MODIIN, Israel and NEW YORK, Feb. 16, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a biotechnology company developing targeted medicines for immune-inflammatory diseases, announced...
VBL Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
14. November 2022 16:05 ET
|
VBL Therapeutics
TEL AVIV, Israel and NEW YORK, Nov. 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage biotechnology company developing targeted medicines for immune-inflammatory...